Diasorin S.p.a. · MIL:DIA

Diasorin — Q3 2011 Earnings Presentation

10 slides from Diasorin's earnings presentation, Nov 11, 2011

  1. Slide 1: Q3'11 & 9M'11 Results Conference Call

    Q3’11 & 9M’11 RESULTS Conference Call November 11th, 2011

  2. Slide 2: Q3'11 and 9M'11 Results Highlights

    Q3’11 AND 9M’11 RESULTS HIGHLIGHTS  Revenues improvement, despite negative exchange rate impact and excluding Murex stock sales in Q3’10 (€ 3mln) Revenues: +3.9% Q3’11 vs. Q3’10 at CER (+0.1% at current exchange rates) +16.2% 9M’11 vs. 9M’10 at CER (+13.7% at current exchange rates)  Significant O

  3. Slide 3: Q3'11 Results: Income Statement

    Q3’11 RESULTS: INCOME STATEMENT Q3 Change €/mln 2011 2010 Amount % Net Revenues without Murex stock sales in 105.2 105.1 +0.1 +0.1% Q3'10 Murex stock sales in Q3'10 - 3.0 Net Revenues 105.2 108.0 (2.9) -2.7% Gross profit 74.7 74.1 +0.6 +0.8% Gross profit margin 71.1% 68.6% S&M (18.7) (17.4) (1.4) +7

  4. Slide 4: Revenues Breakdown: By Technology

    REVENUES BREAKDOWN: BY TECHNOLOGY  CLIA sales still growing although challenging Q3’11 macroeconomic environment Sales: +4.8% Q3’11 vs. Q3’10 +14.6% 9M’11 vs. 9M’10 % on Tot revenues: 73.7% (Q3’11) vs. 70.8% (Q3’10)  ELISA sales continuously decreasing, net of Murex Sales % on Tot revenues: 11.8%

  5. Slide 5: Revenues Breakdown: By Geography

    REVENUES BREAKDOWN: BY GEOGRAPHY Q3 Change €/mln 2011 2010 Amount % % at CER Europe and Africa 44.6 41.7 +2.9 +7.0% +7.3% Central and South America 6.8 6.0 +0.8 +13.3% +17.1% Asia Pacific 11.0 9.1 +1.9 +21.2% +23.5% North America 33.7 38.7 (5.0) -12.9% -4.5% Total without Murex 96.1 95.4 +0.6 +0.7%

  6. Slide 6: Profitability Profile

    PROFITABILITY PROFILE Gross and Operating Result Margins improvement, despite weakness in revenues Q3’11 vs. Q3’10 % on Tot Sales Gross Profit +0.8% 71.1% (from 68.6%) EBITDA +0.6% 42.6% (from 41.2%) EBIT -1.4% 36.1% (from 35.7%) Net Result* -13.8% 19.9% (from 22.5%) * affected by the measurement at

  7. Slide 7: 9M'11 Results: Income Statement

    9M’11 RESULTS: INCOME STATEMENT 01.01 - 09.30 Change €/mln 2011 2010 Amount % Net Revenues without Murex stock sales in 332.3 292.3 +40.0 +13.7% Q3'10 Murex stock sales in Q3'10 - 3.0 Net Revenues 332.3 295.2 +37.1 +12.5% Gross profit 239.0 208.8 +30.3 +14.5% Gross profit margin 71.9% 70.7% S&M (58.

  8. Slide 8: 9M Results: Balance Sheet & Cash Flow

    9M RESULTS: BALANCE SHEET & CASH FLOW €/mln 09.30.2011 12.31.2010 Total tangible assets 58.9 57.6 Total intangible assets 121.8 126.9 Other non-current assets 20.5 20.2 Net Working Capital 127.9 106.4 Other non-current liabilities (30.2) (28.2) Net Capital Employed 299.0 282.9 Net Financial Position

  9. Slide 9: Solid Financial Structure

    SOLID FINANCIAL STRUCTURE OPERATING CASH FLOW € 79.1mln in 9M’11 (before Capex of € 18.9mln) vs. € 74.1mln in 9M’10 (before Capex of € 20.0mln) NET FINANCIAL POSITION +€ 43.8mln at 30/09/11 vs. +€ 33.1mln at 31/12/10, after:  Tax payments: € 45.5mln  Purchases of treasury shares: € 25.1mln  Divid

  10. Slide 10: Shares Buyback Plan

    SHARES BUYBACK PLAN October 4, 2011 Resolution by the Shareholders’ Meeting to purchase Company common shares on October 4, 2011 October 17, 2011 Beginning of the treasury shares purchase program “In accordance with the purposes, terms and conditions authorized by the Shareholders’ Meeting on Octobe

DiaSorin — Q3 2011 Earnings Presentation on 6ix